The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...
The FDA approved a new once-daily Parkinson’s pill in the dopamine agonist class, designed to selectively target receptors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results